{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:04:14Z","timestamp":1784826254221,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.diagmicrobio.2025.116737","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:20:50Z","timestamp":1739013650000},"page":"116737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A real-world investigation into prescribing patterns and effectiveness of ceftolozane\/tazobactam among critically ill patients from SPECTRA"],"prefix":"10.1016","volume":"111","author":[{"given":"Alex","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Thalhalmmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brune","family":"Akrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wirbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre H.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engels N.","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13613-023-01155-4","article-title":"The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference","volume":"13","author":"Dequin","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1751143720914229","article-title":"Comorbidity and survival after admission to the intensive care unit: a population-based study of 41,230 patients","volume":"22","author":"Simpson","year":"2021","journal-title":"J Intensive Care Soc"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0003","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/PROM.S441293","article-title":"The pattern of admission, clinical characteristics, and outcomes among patients admitted to the intensive care unit of a tertiary hospital in Tanzania: a 5-year retrospective review","volume":"14","author":"Kassam","year":"2023","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.iccn.2022.103227","article-title":"Healthcare-associated infections in adult intensive care unit patients: changes in epidemiology, diagnosis, prevention and contributions of new technologies","volume":"70","author":"Blot","year":"2022","journal-title":"Intensive Crit Care Nurs"},{"issue":"13","key":"10.1016\/j.diagmicrobio.2025.116737_bib0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diagmicrobio.2025.116737_bib0006","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116737_bib0007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00134-012-2808-5","article-title":"Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors","volume":"39","author":"Martin-Loeches","year":"2013","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s41030-021-00175-4","article-title":"The impact of risk factors on treatment outcomes of nosocomial pneumonia due to gram-negative bacteria in the intensive care unit","volume":"7","author":"Vo-Pham-Minh","year":"2021","journal-title":"Pulm Ther"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116737_bib0009","first-page":"e36653","article-title":"Mean SOFA score in comparison with APACHE II score in predicting mortality in surgical patients with sepsis","volume":"15","author":"Thakur","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.116737_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0011","unstructured":"Centers for Disease Control and Prevention. Antimicrobial resistance & patient safety portal; 2023. Available from: https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance?tab=antibiotic-resistance. [Accessed 4 April 2024]."},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116737_bib0012","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/molecules25061340","article-title":"Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0013","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12879-021-06229-x","article-title":"Burden of illness in US hospitals due to carbapenem-resistant gram-negative urinary tract infections in patients with or without bacteraemia","volume":"21","author":"Shields","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229393","article-title":"Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections","volume":"15","author":"Tabak","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13756-020-00871-x","article-title":"Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review","volume":"10","author":"Saharman","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116737_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0018","article-title":"Prevalence, outcomes, and predictors of multidrug-resistant nosocomial lower respiratory tract infections among patients in an ICU","volume":"49","author":"Oliveira","year":"2023","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2013concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.116737_bib0020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116737_bib0021","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"issue":"24","key":"10.1016\/j.diagmicrobio.2025.116737_bib0022","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp150049","article-title":"Ceftolozane\u2013tazobactam: a new-generation cephalosporin","volume":"72","author":"Cluck","year":"2015","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116737_bib0023","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"9981","key":"10.1016\/j.diagmicrobio.2025.116737_bib0024","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.116737_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116737_bib0026","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116737_bib0027","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40121-021-00491-x","article-title":"Systematic literature review of real-world evidence of ceftolozane\/tazobactam for the treatment of respiratory infections","volume":"10","author":"Puzniak","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"suppl 1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0028","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.1093\/ofid\/ofab466.1474","article-title":"Ceftolozane\/tazobactam use in critically ill patients receiving intermittent or continuous renal replacement therapy","volume":"8","author":"Henry","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.diagmicrobio.2025.116737_bib53","first-page":"00016-5","article-title":"Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane\/Tazobactam Real-world Analysis (SPECTRA)","volume":"S2213-7165","author":"Soriano","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0030","unstructured":"International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Revised June 2015; Available from: https:\/\/www.pharmacoepi.org\/resources\/guidelines_08027.cfm. [Accessed 12 April 2024]."},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0031","unstructured":"Word Medical Association. Declaration of Helsinki. October 2013; Available from: http:\/\/www.wma.net\/. [Accessed 12 April 2024]."},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0032","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Effective date 22 November 2017: EMA\/873138\/2011; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf. [Accessed 12 April 2024]."},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0033","unstructured":"European Parliament and Council. EU General Data Protection Regulation - Regulation (EU) 2016\/679. 27 April 2016; Available from: http:\/\/data.europa.eu\/eli\/reg\/2016\/679\/2016-05-04. [Accessed 12 April 2024]."},{"issue":"46","key":"10.1016\/j.diagmicrobio.2025.116737_bib0034","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516","article-title":"Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017","volume":"23","author":"Suetens","year":"2018","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12866-021-02135-z","article-title":"Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections\u2013SMART United States 2018\u20132019","volume":"21","author":"Karlowsky","year":"2021","journal-title":"BMC Microbiol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115172","article-title":"Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States","volume":"99","author":"Puzniak","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0037","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116737_bib0038","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1128\/AAC.00431-09","article-title":"Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study","volume":"53","author":"Tacconelli","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2025.116737_bib0039","doi-asserted-by":"crossref","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","article-title":"Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study","volume":"5","author":"McCann","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","article-title":"Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious gram-negative bacterial infections","volume":"357","author":"Bonine","year":"2019","journal-title":"Am J Med Sci"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.116737_bib0041","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0042","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1183\/09031936.06.00049105","article-title":"Appropriateness and delay to initiate therapy in ventilator-associated pneumonia","volume":"27","author":"Luna","year":"2006","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.116737_bib0043","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0044","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13054-021-03787-z","article-title":"Timing of antibiotic therapy in the ICU","volume":"25","author":"Kollef","year":"2021","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2025.116737_bib0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.chest.2020.03.087","article-title":"A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections","volume":"158","author":"Zasowski","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0046","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40121-021-00436-4","article-title":"Cost effectiveness of ceftolozane\/tazobactam compared with meropenem for the treatment of patients with ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"10","author":"Naik","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.116737_bib0047","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.116737_bib0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jhin.2018.11.018","article-title":"Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections","volume":"102","author":"Tabak","year":"2019","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0050","unstructured":"Jayakumar R., Leuthner K., Kullar R., Hewlett D., Nguyen T., Puzniak L. Real-world evaluation of ceftolozane\/tazobactam (C\/T) in severely ill patients with sepsis and\/or bacteraemia. Abstract presented at: the 28th European Congress of Clinical Microbiology and Infectious Diseases; 21-24 April 2018; Madrid, Spain. Abstract P0699."},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.116737_bib0051","first-page":"325","article-title":"Epidemiology of ICU-acquired pneumonia","volume":"24","author":"Ferrer","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.diagmicrobio.2025.116737_bib0052","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. 2016."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:38:37Z","timestamp":1769225917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0732889325000604"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116737","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world investigation into prescribing patterns and effectiveness of ceftolozane\/tazobactam among critically ill patients from SPECTRA","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.116737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116737"}}